Loading…
Fierce Virtual Series: JPM Week 2021 has ended
LL

Luyan LIU

Lyvgen
BD director
Shanghai, China
Lyvgen is an innovative biopharmaceutical company focused on developing novel therapies for cancer. Our proprietary xLink functional platform generated agonistic antibodies with tumour-localized immunostimulatory activities by balancing multiple functions of candidate antibodies, which has helped to generate a number of drug candidates presently in clinical development, including LVGN6051(anti-CD137 agonist Ab) and LVGN7409 (anti-CD40 agonist Ab) . We employ over 50 scientists with global pharmaceutical research and development experience at its research sites in China and the USA. We are looking for collaborations opportunities in R&D, Clinical development and commercialization etc. For more information, please visit our website www.lyvgen.com. If you have any suggestion or question, please feel free to contact me (mailto: luyan.liu@lyvgen.com). Thank you.
Monday, January 11
 

9:30am EST

10:00am EST

10:45am EST

11:15am EST

12:00pm EST

1:00pm EST

1:30pm EST

2:00pm EST

2:30pm EST

3:00pm EST

3:15pm EST

3:35pm EST

 
Tuesday, January 12
 

9:30am EST

10:00am EST

10:50am EST

11:15am EST

12:00pm EST

1:00pm EST

1:35pm EST

2:00pm EST

2:30pm EST

3:00pm EST

3:10pm EST

3:30pm EST

 
Wednesday, January 13
 

9:30am EST

10:00am EST

11:35am EST

11:50am EST

12:00pm EST

1:00pm EST

1:30pm EST

1:50pm EST

2:30pm EST

3:00pm EST

3:35pm EST

3:45pm EST

 
  • Timezone
  • Filter By Date Fierce Virtual Series: JPM Week 2021 Jan 11 -13, 2021
  • Filter By Type
  • Interviews
  • Keynote
  • Networking
  • Panel Discussions
  • Presentations